LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter




The Lyme Disease Network receives a commission from Amazon.com for each purchase originating from this site.

When purchasing from Amazon.com, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet 2020 fund drive


The Lyme Disease Network is a non-profit organization funded by individual donations.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » Medical Questions » Taking Doxy/Antibiotics for Cancer

 - UBBFriend: Email this page to someone!    
Author Topic: Taking Doxy/Antibiotics for Cancer
Tincup
Honored Contributor (10K+ posts)
Member # 5829

Icon 1 posted      Profile for Tincup         Edit/Delete Post   Reply With Quote 
I am going to repost this information in hopes that folks will REALLY read it and pay attention.

I think it is very important. It basically says that they have found that doxy given to cancer patients has helped.

In the mice they studied they gave them 4 of the most prominent cancers humans can get. Then they gave them doxy. The tumors went away. They stopped the doxy and the tumors came back. They re-started the doxy and the tumors went away again.

Plus there are other Lyme/cancer/antibiotic studies that are quite interesting too.

Hope this helps someone.

[Big Grin]

--------------------
www.TreatTheBite.com
www.DrJonesKids.org
www.MarylandLyme.org
www.LymeDoc.org

Posts: 20353 | From The Moon | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
Tincup
Honored Contributor (10K+ posts)
Member # 5829

Icon 1 posted      Profile for Tincup         Edit/Delete Post   Reply With Quote 
The post following this one has the easier to read study on mice... so skip on down if you'd like.

````````````````````````````````````````````````


Virology. 2000 Apr 25;270(1):98-110.

Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele.

Bader, AG., et al
Institute of Biochemistry, University of Innsbruck, Peter-Mayr-Str. 1a, Innsbruck, A-6020, Austria.

To investigate the molecular basis of oncogenesis induced by the v-jun oncogene of avian sarcoma virus 17 (ASV17), we developed a conditional cell transformation system in which transcription of the ASV17 v-jun allele is controlled by a doxycycline-sensitive transactivator (tTA) or a reverse (doxycycline-dependent) transactivator (rtTA), respectively.

Permanent cell lines of quail embryo fibroblasts conditionally transformed by a doxycycline-controlled v-jun allele revert to the normal phenotype within 3 days and lose their ability to grow in soft agar, strictly dependent on the addition or removal of the drug, respectively. The reverted cells are rapidly retransformed on conditional activation of v-jun.

While full-level synthesis of v-jun mRNA and v-Jun protein in these cells is established within 2 and 14 h, respectively, after switching to the permissive conditions, the first morphological alterations are observed after 24 h, and as early as 2 days later the morphology has changed entirely from flat cells resembling normal fibroblasts to spindle-shaped fusiform cells showing a typical jun-transformed phenotype.

Kinetic expression analysis revealed that transcriptional activation of the direct jun target gene BKJ precisely coincides with the establishment of full-level v-Jun protein synthesis.

Furthermore, we have analyzed the expression of a novel candidate v-jun target gene, termed JAC, which shows no sequence homology to known genes. Similar to BKJ, JAC is specifically activated in jun-transformed fibroblasts, and induction of JAC is tightly linked to the conditional expression of oncogenic v-Jun.

These results demonstrate the high stringency of the doxycycline-controlled v-jun expression system, and they also indicate that expression of v-jun in these cells is indispensable for enhanced proliferation, cell transformation, and the induction of specific expression patterns of downstream target genes.

Copyright 2000 Academic Press.

PMID: 10772983 [PubMed - indexed for MEDLINE]

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx


J Am Acad Dermatol. 1997 Feb;36(2 Pt 2):311-4.
Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a.

Kutting, et al
Department of Dermatology, University of Munster, Germany.

We report two patients with low-grade malignant primary cutaneous B cell lymphoma in association with Borrelia burgdorferi infection. Extracutaneous manifestations were ruled out by standard staging procedures.

Infection with Borrelia burgdorferi was confirmed by cultivation from lesional skin in both patients.

In the first patient skin lesions cleared completely after pulse therapy with cefotaxime, whereas in the second patient antibiotic treatment failed.

In this patient, however, skin lesions completely cleared after intralesional injection of interferon alfa-2a.

Antibiotic treatment or intralesional injection of interferon alfa-2a should be considered as a first-line treatment of Borrelia burgdorferi-associated primary cutaneous B cell lymphoma before more aggressive conventional therapeutic modalities (e.g., radiation therapy) are applied.

Publication Types: Case Reports PMID: 9039207 [PubMed - indexed for MEDLINE]

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx


Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13601-6. Epub 2001 Nov 6.

JAC, a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesis.

Hartl M, et al

Institute of Biochemistry, University of Innsbruck, Peter-Mayr-Strasse 1a, A-6020 Innsbruck, Austria. [email protected]

Using subtractive hybridization techniques, we have isolated a gene termed JAC that is strongly and specifically activated in avian fibroblasts transformed by the v-jun oncogene of avian sarcoma virus 17 (ASV17), but not in cells transformed by other oncogenic agents.


Furthermore, JAC is highly expressed in cell lines derived from jun-induced avian fibrosarcomas.

Kinetic analysis using a doxycycline-controlled conditional cell transformation system showed that expression of the 0.8-kb JAC mRNA is induced rapidly upon activation of the oncogenic v-jun allele.

Nucleotide sequence analysis and transcriptional mapping revealed that the JAC gene contains two exons, with the longest ORF confined to exon 2. The deduced 68-amino acid chicken JAC protein is rich in cysteine residues and displays 37% sequence identity to mammalian high-sulfur keratin-associated proteins.

The promoter region of JAC contains a consensus (5'-TGACTCA-3') and a nonconsensus (5'-TGAGTAA-3') AP-1 binding site in tandem, which are both specifically bound by the Gag-Jun hybrid protein encoded by ASV17.

Mutational analysis revealed that the two AP-1 sites confer strong transcriptional activation by Gag-Jun in a synergistic manner.

Ectopic expression of JAC in avian fibroblasts leads to anchorage-independent growth, strongly suggesting that deregulation of JAC is an essential event in jun-induced cell transformation and tumorigenesis.

PMID: 11698665 [PubMed - indexed for MEDLINE]

--------------------
www.TreatTheBite.com
www.DrJonesKids.org
www.MarylandLyme.org
www.LymeDoc.org

Posts: 20353 | From The Moon | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
Tincup
Honored Contributor (10K+ posts)
Member # 5829

Icon 1 posted      Profile for Tincup         Edit/Delete Post   Reply With Quote 
Scientists find way to 'turn off' cancer -

Antibiotic halts aggressive tumours in mice

Tim Radford, Science Editor, Monday October 11, 2004, The Guardian

Scientists in California have found a way to "turn off" a gene that makes cancerous cells lethal.

They eliminated aggressive, incurable liver tumours in laboratory mice in four weeks, they report in an advance paper in Nature today.

The study, based on a gene called Myc, could lead to new ways of treating cancer.

Cancer Research UK scientists in Glasgow, working with colleagues in Seattle, last year worked out the details of how Myc cranks up the rate of growth of dividing cancer cells by sending one of the cell's factories into overdrive.

In cancer, cells divide uncontrollably.

The California team based their studies on mice with genetically modified liver cells. The type of cell that becomes cancerous is called an epithelial cell, and these form cancers in breast, colon and prostate.

So the same approach might work in all of them. Liver cancer is common and difficult to treat.
"This is a terrible cancer.

Anything that is encouraging in liver cancer may be important," said Dean Felsher of Stanford University, who led the research. "The exciting thing is that you can turn cancer cells into something that appears to be normal."

The mice under study had a mutated Myc gene that was constantly on. It produced a Myc protein that served as a kind of conductor, sending a signal to cells to divide.

Cancer cells produce too much Myc protein all the time, and are constantly dividing. Dr Felsher and his colleagues fed the mice an antibiotic called doxycycline, which turned the gene off, and stopped the protein flow.

As long as the mice had the antibiotic diet, they remained healthy. Once the antibiotic was withheld, they developed aggressive liver cancer in 12 weeks.

When they were put back on the diet, all of them showed rapid regression: the liver cancer was eliminated, and liver cells seemed to behave normally.

In effect, the scientists turned the Myc gene on and off like a tap, and turned cancer on and off at the same time.

They also found that some of the apparently normal cells retained the ability to become cancerous, which could explain why cancers often recur after chemotherapy.

Cancer hits one person in three, and kills one in five. In recent years, researchers have concentrated on a number of new approaches.

They have tried to cut off the blood supply to tumours, to halt their growth. They have tested search-and-destroy toxins, designed to make for and eliminate only cancerous cells.

They have experimented with scalpels made of ultrasound, and they have tried to "burn" cancerous cells with infrared radiation.

But cancer is, above all, a disease of the DNA, and British researchers have launched a cancer genome project to collect all the genetic mutations involved in the making of a cancer. There are more than 100.

But the Myc protein seems to play a role in many cases of the disease.


The Glasgow study immediately suggested that it would be a good target. If researchers could find a drug that blocked the action of Myc, they could study its effect on cancer cases.

The Stanford study shows that they were right.
But what works in mice may not work so well in humans.

The next step is to hunt for a drug that would be safe for human patients, and yet have the same impact.

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx


Int J Cancer. 2004 Jun 20;110(3):336-42.

Reversible lymphomagenesis in conditionally c-MYC expressing mice.

Marinkovic D, Marinkovic T, Mahr B, Hess J, Wirth T.

Department of Physiological Chemistry, Ulm University, Ulm, Germany.

It is well documented that deregulation of MYC leads to tumor development, yet many aspects of this process are only partially understood. We have established a transgenic mouse model in which c-MYC is conditionally expressed in lymphoid cells using the tetracycline-regulated system of gene regulation.

Mice with continuously expressed transgenic c-MYC died of invasive T- or B-cell lymphomas within 4 months.

Lymphomas developing in transgenic mice were c-MYC dependent since doxycycline treatment led to tumor regression.

Using transplantation of established tumor cell lines labeled with GFP, we followed the fate of neoplastic cells in recipients upon MYC inactivation.

This approach allowed us to elucidate both apoptosis and differentiation as mechanisms of tumor elimination.

Comparative genomic hybridization (CGH) and FISH analyses were performed in order to analyze possible chromosomal aberrations induced by c-MYC.

We observed that overexpression of c-MYC is sufficient to induce recurrent patterns of genomic instability.

The main observation was a gain of genomic material that corresponded to chromosome 15 in several T-cell tumors, which could be identified as trisomy. Copyright 2004 Wiley-Liss, Inc.

PMID: 15095297 [PubMed - indexed for MEDLINE]

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Virology. 1999 Jan 20;253(2):193-207.

Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele.

Oberst C, Hartl M, Weiskirchen R, Bister K.

Institute of Biochemistry, University of Innsbruck, Peter-Mayr-Str. 1a, Innsbruck, A-6020, Austria.

To investigate the molecular basis of oncogenesis induced by the v-myc oncogene of avian myelocytomatosis virus MC29, we developed a conditional cell transformation system in which expression of the MC29 v-myc allele is dependent on a doxycycline-sensitive transactivator (tTA).

Clonal lines of quail embryo fibroblasts transformed by doxycycline-controlled v-myc revert to the normal phenotype and lose their ability to grow in soft agar after the addition of doxycycline.

Repression of v-myc causes the cells to withdraw from the cell cycle, and long-term survival in culture requires reexpression of v-myc.

Although complete repression of v-myc mRNA and v-Myc protein in these cells occurs within 14 h after the addition of doxycycline, the first morphological alterations are observed after 24 h, and after 3 days, the morphology changed entirely from small rounded cells showing a typical myc-transformed phenotype to large flat cells resembling normal fibroblasts.

Cells exposed to doxycycline for 3 days reexpressed v-myc within 24 h after withdrawal of the drug from the culture medium, partial retransformation occurred after 2 days, and complete morphological transformation was reestablished after 6 days.

Analogous results were obtained with a cell line in which expression of the v-myc allele is dependent on a reverse transactivator (rtTA) that is activated by doxycycline.

The striking differential expression of known transformation-sensitive genes and of new candidate v-myc target genes revealed the tightness of the doxycycline-controlled v-myc expression system.

The data also indicate that expression of v-myc in these cells is indispensable for enhanced proliferation, transformation, and immortalization. Copyright 1999 Academic Press.

PMID: 9918878 [PubMed - indexed for MEDLINE]

--------------------
www.TreatTheBite.com
www.DrJonesKids.org
www.MarylandLyme.org
www.LymeDoc.org

Posts: 20353 | From The Moon | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
treepatrol
Honored Contributor (10K+ posts)
Member # 4117

Icon 1 posted      Profile for treepatrol     Send New Private Message       Edit/Delete Post   Reply With Quote 
Well there Tc GOOD NEWS HUH? [Big Grin]
Dang girl all the searching I do and you find it!! i am a slippin [bonk]

--------------------
Do unto others as you would have them do unto you.
Remember Iam not a Doctor Just someone struggling like you with Tick Borne Diseases.

Newbie Links

Posts: 10564 | From PA Where the Creeks are Red | Registered: Jun 2003  |  IP: Logged | Report this post to a Moderator
Jellybelly
Frequent Contributor (1K+ posts)
Member # 7142

Icon 1 posted      Profile for Jellybelly   Author's Homepage         Edit/Delete Post   Reply With Quote 
I have really begun to believe that we will eventually find out that most diseases/illnesses are caused by some sort of pathogen. Just like with autoimmunity, I am really thinking that things don't just go wrong all the time when people get sick. They got something. True there may be a genetic weakness, but it is likely that weakness and the invading pathogen that makes us sick. There are soooo many pathogens that have yet to be discovered. Medicine has only seen the very tip of this iceberg.

The fact that they can give a human cancer to mice by simply putting it in them makes me really wonder in what ways we are spreading all of this stuff person to person. ESPECIALLY when it comes to blood transfusions.....puttng someone elses blood into you, is also putting all kinds of other stuff including their bugs!!! BLAH!!

Posts: 1251 | From california | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
CaliforniaLyme
Frequent Contributor (5K+ posts)
Member # 7136

Icon 1 posted      Profile for CaliforniaLyme     Send New Private Message       Edit/Delete Post   Reply With Quote 
Yup!*)!*)!*!!!!!!!!!!!!!!!!!!

Abx save lives*)!*)!*!

They save mine on a daily basis*)!*)*!

--------------------
There is no wealth but life.
-John Ruskin

All truth goes through 3 stages: first it is ridiculed: then it is violently opposed: finally it is accepted as self evident. - Schopenhauer

Posts: 5639 | From Aptos CA USA | Registered: Apr 2005  |  IP: Logged | Report this post to a Moderator
Lymetoo
Moderator
Member # 743

Icon 1 posted      Profile for Lymetoo     Send New Private Message       Edit/Delete Post   Reply With Quote 
That's amazing!

--------------------
--Lymetutu--
Opinions, not medical advice!

Posts: 96222 | From Texas | Registered: Feb 2001  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code� is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | LymeNet home page | Privacy Statement

Powered by UBB.classic™ 6.7.3


The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:

The Lyme Disease Network of New Jersey
907 Pebble Creek Court, Pennington, NJ 08534 USA


| Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Contact Us

© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to Terms and Conditions.